CTKB - Company ID 0001831915
The table below shows Cytek Biosciences, Inc.'s balance sheet line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & equivalents | $90.85M | $98.72M | $167.30M | $296.60M | $364.62M |
| Short-term investments | - | - | - | - | - |
| Receivables | $62.51M | $60.59M | $55.93M | $48.86M | $29.76M |
| Inventory | $48.43M | $43.89M | $60.88M | $48.15M | $32.17M |
| Total current assets | $392.00M | $396.45M | $392.06M | $454.02M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $431.73M |
| Property, plant & equipment | $18.01M | $17.96M | $18.41M | $13.68M | $5.85M |
| Goodwill | $16.70M | $16.66M | $16.18M | $10.14M | $10.14M |
| Total assets | $461.54M | $499.50M | $494.46M | $519.48M | $463.31M |
| Accounts payable | - | - | - | - | - |
| Total current liabilities | $77.80M | $67.66M | $56.23M | $49.04M | $33.18M |
| Long-term debt | - | - | - | - | - |
| Total liabilities | $119.80M | $103.76M | $101.39M | $93.93M | $57.92M |
| Retained earnings | -$101.74M | -$35.20M | -$29.18M | -$17.03M | -$19.61M |
| Total equity | $341.74M | $395.74M | $393.06M | $425.55M | $405.38M |